Breast Cancer Clinical Trials
Adult Clinical Trials Main Page
CPMC Cancer Services
Further protocol information can be found on the links below at ClinicalTrials.gov
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
|---|---|---|---|
| CPMC Oncologists CPMC Oncologists Contact: Brenda Eng 415-600-3241 Email engb@cpmcri.org | A Phase III Trial Of Continuous Schedule AC + G Q2 Week Schedule AC, Followed By Paclitaxel Given Either Every 2 Weeks Or Weekly For 12 Weeks As Post-Operative Adjuvant Therapy In Node-Positive Or High-Risk Node Negative Breast Cancer. SWOG S0221 | Subjects with completely resected node-positive or high-risk node negative (stage I-III) Breast Cancer | Active/Enrolling |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Phase III Trial of Bisphosphonates as adjuvant Therapy for Primary Breast Cancer | Subjects with confirmed primary invasive adenocarcinoma of the breast, Stage I, II, III, with no evidence of metatastic disease | Active/Enrolling |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial--A Phase III observational trial evaluating the role of ovarian function suppression and the role of Exemestane as adjuvent therapies for premenopausal women with endocrine responsive breast cancer | Premenopausal women with biopsy confirmed resected breast cancer. | Active/Enrolling |
| Principal Investigator: NCI National Cancer Institute Contact: Ron Frianeza 415-600-3027 Email FrianeR@cpmcri.org | A Randomized Phase III Trial Of Weekly Paclitaxel Compared To Weekly Nanoparticle Albumin Bound Nab-Paclitaxel Or Ixabepilone Combined With Bevacizumab As First-Line Therapy For Locally Recurrent Or Metastatic Breast Cancer | Patients with breast cancer where the cancer has returned after surgery to remove the cancer. | Active/Enrolling |
| Principal Investigator: NCI National Cancer Institute Contact: Tracy Paris 415-600-3241 Email parist@cpmcri.org | A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI)Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, II Breast Cancer | Females 18 years or greater with histological proof of phyllodes tumour that has been resected | Active/Enrolling |
| Principal Investigator: NCI National Cancer Institute Contact: Ron Frianeza 415-600-3027 Email FrianeR@cpmcri.org | A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AL) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer. | Females 18 years or greater with histologically confirmed invasive carcinoma of the breast | Active/Enrolling |
| Principal Investigator: NCI National Cancer Institute Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | A Double Blind Randomization To Letrozole Or Placebo For Women Previously Diagnosed With Primary Breast Cancer Completing Five Years Of Adjuvant Aromatase Inhibitoreither As Initial Therapy Or After Tamoxifen (Including Those In The Ma.17 Study) | Patients who are ErbB-2 positive with locally advanced or metastatic breast cancer | Active/ Closed to Enrollment |
| Principal Investigator: NCI National Cancer Institute Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Cyclophosphamide and Doxorubicin (CA)(4 vs. 6 cycles) Versus Paclitaxel (4 vs. 6 cylces)as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: a 2x2 Factorial Phase III Randomized Study | Patients with breast cancer where the cancer has returned after surgery to remove the cancer. | Active/ Closed to Enrollment |
| Principal Investigator: NCI National Cancer Institute Contact: Brenda Eng 415-600-1775 Email engb@cpmcri.org | Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following standard adjuvent chemotherapy in early stage, hormone-receptor negative breast cancer | Females with bilateral synchronous breast cancer where tumours were diagnosed no more then 1 month apart. | Active/ Closed to Enrollment |
| Principal Investigator: NCI National Cancer Institute Contact: Ron Frianeza 415-600-3027 Email FrianeR@cpmcri.org | A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy | Subjects who have locally recurrent or metastatic breast cancer | Active/ Closed to Enrollment |
updated: 9/2010
Back to top